Skip to main content
. Author manuscript; available in PMC: 2015 Aug 13.
Published in final edited form as: Cochrane Database Syst Rev. 2014 Aug 13;8:CD003256. doi: 10.1002/14651858.CD003256.pub2

Comparison 8. Bleomycin versus ABV (non-RCT).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Mortality 1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.87, 1.36]
2 Clinical response 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
 2.1 Complete response 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
 2.2 Partial response 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.86]
 2.3 Stable disease 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.47, 1.63]
 2.4 Progression 1 24 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.67, 179.29]
3 Adverse events 1 24 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.67, 179.29]